Paride Liscio
University of Perugia
13 Papers
49 Citations
Paride Liscio is an academic researcher from University of Perugia. The author has contributed to research in topics: NAD+ kinase & Chemistry. The author has an hindex of 9, co-authored 12 publications.
Chat about Author
Papers
De novo NAD + synthesis enhances mitochondrial function and improves health
Elena Katsyuba,Adrienne Mottis,Marika Zietak,Marika Zietak,Francesca De Franco,Vera van der Velpen,Karim Gariani,Karim Gariani,Dongryeol Ryu,Dongryeol Ryu,Lucia Cialabrini,Olli Matilainen,Olli Matilainen,Paride Liscio,Nicola Giacchè,Nadine Stokar-Regenscheit,Nadine Stokar-Regenscheit,David Legouis,Sophie de Seigneux,Julijana Ivanisevic,Nadia Raffaelli,Kristina Schoonjans,Roberto Pellicciari,Johan Auwerx +23 more
TL;DR: Genetic or pharmacological inhibition of α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase increases NAD+ and improves mitochondrial function in nematodes and mice, and may have therapeutic potential in kidney and liver disease.
390
Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Martina Ferri,Paride Liscio,Andrea Carotti,Stefania Asciutti,Roccaldo Sardella,Antonio Macchiarulo,Emidio Camaioni +6 more
TL;DR: The most promising TNKSi hitherto reported in literature, acting in vivo models of Wnt-driven cancers are reviewed, and comprehensive structure property relationships emerging from the hit evolution processes and preclinical results are provided.
54
From polypharmacology to target specificity: the case of PARP inhibitors.
TL;DR: Challenges exist in understanding the polypharmacology of current PARP inhibitors as well as developing highly selective chemical tools to unravel specific functions of each member of the superfamily.
34
Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: From TIQ-A to HYDAMTIQ
Roberto Pellicciari,Emidio Camaioni,Adam M. Gilbert,Antonio Macchiarulo,Jack A. Bikker,Falgun Shah,Joel Bard,Gabriele Costantino,Antimo Gioiello,Graeme M. Robertson,Paola Sabbatini,Francesco Venturoni,Paride Liscio,Andrea Carotti,Daniele Bellocchi,Andrea Cozzi,A. G. Wood,Cathleen Gonzales,Margaret M. Zaleska,John W. Ellingboe,Flavio Moroni +20 more
TL;DR: The design, synthesis and biological appraisal of novel potent PARP-1 inhibitors, and the results of HYDAMTIQ in models of brain ischemia as well as its preliminary physicochemical and pharmacokinetic characterization qualify HYDamTIQ as a novel lead candidate for advancement to clinical settings of brainIschemia.
18
Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy.
Jean-Rémy Marchand,Andrea Carotti,Daniela Passeri,Paolo Filipponi,Paride Liscio,Emidio Camaioni,Roberto Pellicciari,Antimo Gioiello,Antonio Macchiarulo +8 more
TL;DR: Fluorescence anisotropy assays support such a mechanism, providing the first experimental evidence that HYDAMTIQ, a potent PARP inhibitor with neuroprotective properties, is less potent than Olaparib to trap PARP-1/DNA complex.
16